Background: The aim of this study was to report on sirolimus activity in a series of patients with hemangioendothelioma (HE) treated at the National Cancer Institute, Milan (Istituto Nazionale Tumori; INT) and within the Italian Rare Cancer Network ("Rete Tumori Rari"; RTR).
Methods: We retrospectively reviewed patients with advanced and progressing epithelioid hemangioendothelioma (EHE) treated with sirolimus at the INT and/or within the RTR. Pathologic review and molecular analysis for WWTR1 rearrangement were performed. Sirolimus was administered until unacceptable toxicity or progression, with the dose being adjusted to reach target plasma levels of 15-20 ng/dL. Responses were assessed using the Response Evaluation Criteria In Solid Tumors (RECIST) criteria.
Results: Since 2005, 18 patients (17 EHE, 1 retiform HE; 1 locally advanced, 17 metastatic; WWTR1 rearrangement: 16) have been identified, with 17/18 patients being evaluable for response. Mean sirolimus daily dose was 4.5 mg. According to RECIST, best responses in EHE were 1 partial response (PR), 12 stable disease (SD), and 3 progressive disease (PD); the patient with retiform HE also achieved a PR, lasting >2 years. Four patients with a reversed interval progression on interruption were observed. Median overall survival was 16 months, and median progression-free survival was 12 months (range 1-45), with four patients progression-free at 24 months. The clinical benefit (complete response [CR] + PR + SD >6 months) was 56 %. Seven patients receiving sirolimus experienced an increase in pleural/peritoneal effusion plus worsening of tumor-related symptoms; six of these patients died within 1-8 months from evidence of effusion progression, while a RECIST PD was assessed in two of seven patients.
Conclusions: A clinical benefit was achieved in 56 % of patients receiving sirolimus, which lasted >24 months in four patients. Most patients with pleural effusion did not benefit from sirolimus and had a poor outcome.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1245/s10434-016-5331-z | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Differences in disease severity and in-hospital mortality in patients hospitalised for pneumonia with and without intellectual disabilities: A matched-pair retrospective cohort study using nationwide in-patient database.
J Intellect Dev Disabil
March 2022
Department of Clinical Epidemiology and Health Economics, School of Public Health, The University of Tokyo, Tokyo, Japan.
Background: We examined the association between intellectual disabilities (ID) and pneumonia severity at admission.
Methods: We extracted patients admitted to hospital for pneumonia from July 2010 to March 2018 using the Diagnosis Procedure Combination database. We measured pneumonia severity using the A-DROP system.
Study of decision-making capacity in Prader-Willi syndrome with a Gambling Task.
J Intellect Dev Disabil
March 2022
Laboratoire de Psychologie, University of Bordeaux, Bordeaux, France.
Background: The present study investigated decision-making in patients with Prader-Willi syndrome (PWS) using the Soochow Gambling Task (SGT). The objective was to assess whether adults with PWS have impaired hot executive functions and whether the deficit is specific to PWS or linked to intellectual disabilities.
Method: The SGT performance of 26 adults with PWS was compared to that of 26 healthy adults matched on chronological age, and to that of 26 adults with intellectual disabilities but without PWS, matched on intellectual quotient level and chronological age.
The effectiveness of schema therapy in offenders with intellectual disabilities: a case series design.
J Intellect Dev Disabil
September 2022
Faculty of Psychology and Neuroscience, Maastricht University, Maastricht, The Netherlands.
Background: In forensic settings, patients with intellectual disabilities are overrepresented. A relative novel treatment approach for this population is schema therapy. The goals of schema therapy for offenders with intellectual disabilities are to reduce maladaptive emotional states and to reinforce healthy emotional states and enhancing the patient's ability to ask for help.
View Article and Find Full Text PDFIdentification of TRAPPC4 as a Key Autoantigen in Immune-Related Pancytopenia: Epitope Characterization and Immune Activation Mechanisms.
Turk J Haematol
January 2025
Tianjin Medical University General Hospital, Department of Hematology, Tianjin, P. R. China.
Objective: Immune-related pancytopenia (IRP) is characterized by autoantibody-mediated destruction or suppression of bone marrow cells, leading to pancytopenia. This study aimed to explore the role of TRAPPC4 (trafficking protein particle complex subunit 4) as a key autoantigen in IRP, including epitope identification and immune activation mechanisms.
Methods: A total of 90 participants were included in the study, divided into four groups: 30 newly diagnosed IRP patients, 25 IRP remission patients, 20 patients with control hematologic conditions (severe aplastic anemia [SAA] and myelodysplastic syndrome [MDS]), and 15 healthy controls.
Aneurysm at the Trunk of the Medial-Type Persistent Trigeminal Artery Associated with Facial Pain : A Rare Case Report.
J Korean Neurosurg Soc
January 2025
Department of Neurosurgery, Daejeon St. Mary's Hospital, The Catholic University of Korea, Daejeon, Korea.
Persistent trigeminal artery (PTA) is the most common residual manifestation of persistent carotid-vertebrobasilar anastomosis, with the medial-type (intrasellar or sphenoidal) PTA being exceptionally rare. Aneurysms originating from the PTA trunk are not common. We present a unique case of an aneurysm located at the trunk of the medial-type PTA in a patient presenting with trigeminal neuralgia who successfully received endovascular treatment.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!